Check Cap Ltd (NASDAQ:CHEK) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $4.42 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 115 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently weighed in on CHEK shares. HC Wainwright restated a “buy” rating and set a $7.00 price target (up from $6.00) on shares of Check Cap in a report on Thursday, September 28th. Zacks Investment Research upgraded Check Cap from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday, October 3rd. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of Check Cap in a report on Wednesday, September 27th. Finally, ValuEngine upgraded Check Cap from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th.

A hedge fund recently raised its stake in Check Cap stock. Sabby Management LLC increased its holdings in Check Cap Ltd (NASDAQ:CHEK) by 467.9% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,418,893 shares of the medical research company’s stock after buying an additional 1,169,061 shares during the quarter. Check Cap comprises approximately 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest position. Sabby Management LLC owned about 8.36% of Check Cap worth $2,724,000 as of its most recent SEC filing. 19.13% of the stock is owned by institutional investors and hedge funds.

Check Cap (NASDAQ:CHEK) opened at $0.88 on Friday. Check Cap has a twelve month low of $0.80 and a twelve month high of $2.64.

TRADEMARK VIOLATION NOTICE: “Zacks: Check Cap Ltd (CHEK) Given $4.42 Consensus Price Target by Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/09/zacks-check-cap-ltd-chek-given-4-42-consensus-price-target-by-brokerages.html.

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check Cap Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap Ltd and related companies with MarketBeat.com's FREE daily email newsletter.